A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG+ hybridomas in comparison to its recombinant allergen-drug conjugate. Issue 1 (6th December 2022)
- Record Type:
- Journal Article
- Title:
- A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG+ hybridomas in comparison to its recombinant allergen-drug conjugate. Issue 1 (6th December 2022)
- Main Title:
- A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG+ hybridomas in comparison to its recombinant allergen-drug conjugate
- Authors:
- Daramola, A K
Akinrinmade, O A
Fajemisin, E A
Naran, K
Mthembu, N
Hadebe, S
Brombacher, F
Huysamen, A M
Fadeyi, O E
Hunter, R
Barth, S - Abstract:
- Summary: Introduction: Current treatments for asthma help to alleviate clinical symptoms but do not cure the disease. In this study, we explored a novel therapeutic approach for the treatment of house dust mite allergen Der p 1induced asthma by aiming to eliminate specific population of B-cells involved in memory IgE response to Der p 1. Materials and Methods: To achieve this aim, we developed and evaluated two different proDer p 1-based fusion proteins; an allergen-toxin (proDer p 1-ETA) and an allergen-drug conjugate (ADC) (proDer p 1-SNAP-AURIF) against Der p 1 reactive hybridomas as an in vitro model for Der p 1 reactive human B-cells. The strategy involved the use of proDer p 1 allergen as a cell-specific ligand to selectively deliver the bacterial protein toxin Pseudomonas exotoxin A (ETA) or the synthetic small molecule toxin Auristatin F (AURIF) into the cytosol of Der p 1 reactive cells for highly efficient cell killing. Results: As such, we demonstrated recombinant proDer p 1 fusion proteins were selectively bound by Der p 1 reactive hybridomas as well as primary IgG1 + B-cells from HDM-sensitized mice. The therapeutic potential of proDer p 1-ETAʹ and proDer p 1-SNAP-AURIF was confirmed by their selective cytotoxic activities on Der p 1 reactive hybridoma cells. The allergen-toxin demonstrated superior cytotoxic activity, with IC50 values in the single digit nanomolar value, compared to the ADC. Discussions: Altogether, the proof-of-concept experiments in thisSummary: Introduction: Current treatments for asthma help to alleviate clinical symptoms but do not cure the disease. In this study, we explored a novel therapeutic approach for the treatment of house dust mite allergen Der p 1induced asthma by aiming to eliminate specific population of B-cells involved in memory IgE response to Der p 1. Materials and Methods: To achieve this aim, we developed and evaluated two different proDer p 1-based fusion proteins; an allergen-toxin (proDer p 1-ETA) and an allergen-drug conjugate (ADC) (proDer p 1-SNAP-AURIF) against Der p 1 reactive hybridomas as an in vitro model for Der p 1 reactive human B-cells. The strategy involved the use of proDer p 1 allergen as a cell-specific ligand to selectively deliver the bacterial protein toxin Pseudomonas exotoxin A (ETA) or the synthetic small molecule toxin Auristatin F (AURIF) into the cytosol of Der p 1 reactive cells for highly efficient cell killing. Results: As such, we demonstrated recombinant proDer p 1 fusion proteins were selectively bound by Der p 1 reactive hybridomas as well as primary IgG1 + B-cells from HDM-sensitized mice. The therapeutic potential of proDer p 1-ETAʹ and proDer p 1-SNAP-AURIF was confirmed by their selective cytotoxic activities on Der p 1 reactive hybridoma cells. The allergen-toxin demonstrated superior cytotoxic activity, with IC50 values in the single digit nanomolar value, compared to the ADC. Discussions: Altogether, the proof-of-concept experiments in this study provide a promising approach for the treatment of patients with house dust mite-driven allergic asthma. Graphical Abstract: … (more)
- Is Part Of:
- Immunotherapy advances. Volume 3:Issue 1(2023)
- Journal:
- Immunotherapy advances
- Issue:
- Volume 3:Issue 1(2023)
- Issue Display:
- Volume 3, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 3
- Issue:
- 1
- Issue Sort Value:
- 2023-0003-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-12-06
- Subjects:
- Der p 1 -- house dust mite -- Allergen-toxin -- allergen-drug conjugate -- Auristatin F and Pseudomonas exotoxin A
Immunotherapy -- Periodicals
615.37 - Journal URLs:
- https://academic.oup.com/immunotherapyadv/ ↗
- DOI:
- 10.1093/immadv/ltac023 ↗
- Languages:
- English
- ISSNs:
- 2732-4303
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 25700.xml